

## Publications



### **A. THESIS for Post Graduation in Pathology**

A Histopathologic Study of Malignant Tumors in Children at Christian Medical College & Hospital (1975 to 1982), Ludhiana, India. Advisor: (The late) S. D. Khanna, MD. Ph.D. Professor, Pathology, CMCH, India. Pages 1-209. Punjab University, India, 1984.

### **B. Recent Publications in Peer Reviewed Journals (out of a total of 75)**

Singh M, Darcy KM, Brady WE, Weber Z, Akalin A, Whitney CW, Zaino R, Ramirez N and Leslie KK. Significance of e-cadherin and p16 in advanced endometrial cancer: A Gynecologic Oncology Group phase II study. *Gynecologic Oncology* Nov 2011; 123(2):320-8. Aug 1 '2011 E pub ahead of print.

Singh M, Pal T. Voice recognition technology implementation in surgical pathology: Advantages and limitations. *Archives of Path & Lab Med.* Nov 2011; 135 (11):1476-81.

Hines LM, Risendal B, Byers T, Mengshol S, Lowery J and Singh M,. Ethnic differences in breast tumor subtypes among Hispanic women. *J Women's Health* (Larchmt). 2011 Oct; 20 (10): 1543-50. [July 1. E pub ahead of print]

Singh, M, Mugler K, Hailoo D, Nemesure B, Torkko K, Shroyer KR. Expression of Transferrin Receptor in a spectrum of benign to malignant breast disease. *Appl Immunohistochem Mol Morphol.* 2011 Oct; 19(5):417-23. [Feb 2. Epub ahead of print].

Dinges M, Jaggassarsingh D, Peterson T, Singh M. Lobular endocervical glandular hyperplasia extensive mucinous metaplasia of the endometrium and endometrial mucinous adenocarcinoma in situ. *Gynecologic Oncology* Sept 2011, 122; 686-688. May 21 '2011, E pub ahead of print.

Harmon B, Friedman K and Singh M. Pediatric Solid Malignant Neoplasms: A Comparative Analysis. *Indian J Path and Microbiol.* July-Sept 2011; 54(3):514-9.

Lowery JT, Byers T, Kittelson J, Hokanson JE, Mouchawar J, Lewin J, Merrick D, Hines L, Singh M: Differential expression of prognostic biomarkers between interval and screen-detected breast cancer: does age or family history matter? *Breast Cancer Treat & Res.* 2011 Aug;129(1):211-9. March 24' 2011 (E pub ahead of print).

Singh M, Mockler D, Akalin A, Burke S, and Shroyer KR. Dual localization of p16<sup>INK4a</sup> and Ki-67 improves specificity for HSIL and AGUS. *Cancer Cytopathology* June 2011 (in press).

Samarawardana P, Singh M, Shroyer KR. Dual stain immunohistochemical localization of p16 INK4a and Ki-67: a synergistic approach to identify clinically significant cervical mucosal lesions. *Appl Immunohistochem Mol Morphol.* 19 May 2011 (E pub ahead of print).

Lowery JT, Byers T, Hokanson JE, Kittelson J, Lewin J, Risendal B, Singh M, Mouchawar J. Complementary approaches to assessing risk factors for interval breast cancer. *Cancer Causes & Control* 2011 Jan, 22(1):23-31.

Heimann A , Maini G, Hwang S, Shroyer K and Singh M. Use of Telecytology for the immediate assessment of CT guided and endoscopic FNA cytology: advantages and pitfalls. *Diagnostic Cytopathology* E pub ahead of print Dec 31, 2010. PMID: 21197649.

Jaggessarsingh D. Muram-Zborovski T.M., Bemis L, Robinson W.A., Finlayson C, Singh M. Unique profile of adenoid cystic carcinoma: A triple negative breast tumor with paradoxical features, a case report and review of literature. Featured article. *LabMedicine* 2010; 41(12):713

Samarawardana P, Dehn D, Singh M, Franquemont D, Thompson C, Torkko K, Homer P, Burke S, Titmus M, Nayi V, Shroyer K. p16INK4a is superior to high risk HPV testing in cervical cytology for the prediction of underlying high grade dysplasia. *Cancer Cytopathol.* 2010 Jun 25;118(3):146-56.

Weitzel LR, Byers T, Allen J, Finlayson C, Helmke SM, Hokanson JE, Hunsucker SW, Murphy JR, Newell K, Queensland KM, Singh M, Wischmeyer PE, Duncan MW, Elias A. Discovery and verification of protein differences between Er positive/Her2/neu negative breast tumor tissue and matched adjacent normal breast tissue. *Breast Cancer Res Treat.* 124 (2): 297-305, Nov 2010. Epub 2010 Jan 20.

Carneiro C, Hurtubis CA, Singh M and Robinson WA. Desmoid tumors of the right rectus abdominus muscle in postpartum women. *Arch Gynecol Obstet.* 2009 Jun;279(6):869-73. 2008 Nov 20. [Epub ahead of print].

Brooks G, Borges V, Singh M, Rabinovitch R, Finlayson C and Elias A. A perimenopausal woman with a small ER+/HER2+, node negative breast cancer. *Oncology (Williston Park)* 2008 Oct;22(11):1270-6.

Singh M, Speolstra NS, Jean A, Howe EN, Shroyer KS, Torkko KC, Clark HR, Darling D, Horwitz KB, Broaddus RR and Richer JK. ZEB 1 expression in type I vs type II endometrial cancers: a marker of aggressive disease. *Modern Pathology* 2008 21(7):912-23, Epub May 16, 2008. Review of this manuscript published in CAP Today, January 2009.

Klopper JP, Berenz A, Hays WR, Sharma V, Pugazhenthii U, Janssen J, Singh M, Bissonnette RP and Haugen BR. In Vivo and Microarray Analysis of the Treatment Effects of a Retinoid on the Anaplastic Thyroid Carcinoma Cell Line DRO-90. *Clinical Cancer Research* 2008;14(2), 589-96. Erratum in: *Clin Cancer Res.* 2009 Jan 1;15(1):416.

Raina K, Rajamanickam S, Deep G, Singh M, Agarwal R and Agarwal C. Chemopreventive effects of oral gallic acid feeding on tumor growth and progression in TRAMP mice. *Mol Cancer Therapeutics* 2008;7(5):1258-67. Epub Apr 29, 2008.

Harvell DM, Spoelstra NS, Singh M, Finlayson C, Phang T, Trapp S, Hunter L, Borges VB, Elias A, KB Horwitz and JK Richer. Molecular Signatures of Response to Neoadjuvant Endocrine Therapy for Breast Cancer. *Breast Cancer Res Treat.* 2008 Dec;112(3):475-88. Epub 9 Mar, 2008.

Harvell DM, Richer JK, Singh M, Spoelstra N, Finlayson C, Borges VB, Elias A, and KB Horwitz. Estrogen regulated gene expression in response to neoadjuvant hormone therapy of breast cancers: Tamoxifen agonist effects dominate in the presence of aromatase inhibitor. *Breast Cancer Res Treat.* 2008 Dec;112(3):489-501. Epub Mar 13, 2008